Successful treatment with isavuconazole of subcutaneous phaeohyphomycosis in a kidney transplant recipient.
Aged
Alternaria
/ immunology
Antifungal Agents
/ therapeutic use
Humans
Immunocompromised Host
Kidney Failure, Chronic
/ surgery
Kidney Transplantation
/ adverse effects
Male
Nitriles
/ therapeutic use
Phaeohyphomycosis
/ diagnosis
Pyridines
/ therapeutic use
Subcutaneous Tissue
/ microbiology
Treatment Outcome
Triazoles
/ therapeutic use
Alternaria
Phaeohyphomycosis
isavuconazole
transplantation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
12
06
2019
revised:
02
08
2019
accepted:
04
10
2019
pubmed:
17
10
2019
medline:
1
5
2020
entrez:
17
10
2019
Statut:
ppublish
Résumé
Phaeohyphomycosis is a diverse group of uncommon mycotic infections caused by dematiaceous fungi which appears to be increasing in incidence, particularly in transplant recipients. Alternaria is the most frequent isolated genus. Subcutaneous, pulmonary and disseminated disease are the most common sites of Alternaria infection in solid organ transplant recipients. We report the first case, to our knowledge, of a kidney transplant recipient with Alternaria alternata subcutaneous infection who was successfully treated with isavuconazole.
Substances chimiques
Antifungal Agents
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13197Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Boyce RD, Deziel PJ, Otley CC, et al. Phaeohyphomycosis due to Alternaria species in transplant recipients. Transpl Infect Dis. 2010;12:242-250.
Huprikar S, Shoham Sand the AST Infectious Diseases Community of Practice. Emerging fungal infections in solid organ transplantation. Am J Transplant. 2013;13:262-271.
Schieffelin JS, Garcia-Diaz JB, Loss GE, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis. 2014;16:270-278.
McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: results from the Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol. 2015;53:440-446.
Haridasan S, Parameswaran S, Bheemanathi SH, et al. Subcutaneous phaeohyphomycosis in kidney transplant recipients: A series of seven cases. Transpl Infect Dis. 2017;19:e12788.
Revankar SG, Baddley JW, Chen SC, et al. A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: an analysis of 99 proven/probable cases. Open Forum Infect Dis. 2017;26(4): ofx200. https://doi.org/10.1093/ofid/ofx200
Pastor FJ, Guarro J. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol Infect. 2008;14(8):734-746.
Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(3):47-75.
Badali H, De Hoog GS, Curfs-Breuker I, Andersen B, Meis JF. In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. J Antimicrob Chemother. 2009;63:1295-1297.
Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:1558-1565.
Gonzàlez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47(1):71-76.
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163-174.
Chitasombat MN, Kontoyiannis DP. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opin Pharmacother. 2015;16(10):1543-1558.
Donnelley MA, Zhu ES, Thompson GR III. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79-86.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760-769.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: open-label trial and contemporaneous case-control analysis. Lancet Infect Dis. 2016;16:828-837.
National Institutes of Health Isavuconazole (BAL8557) in the treatment of candidemia and other invasive Candida infections ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00413218
Cornely OA, Mullane KM, Ostrosky-Zeichner L, et al. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018;61:518-533.
Kim T, Jancel T, Kumar P, Freeman AF. Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther. 2015;40(5):609-611.
Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6:76-85.
Rivosecchi RM, Clancy CJ, Shields RK, et al. Effects of isavuconazole on the plasma concentrations of tacrolimus among solid-organ transplant patients. Antimicrob Agents Chemother. 2017;61:e00970-e1017.
Jenks JD, Salzer HJF, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033-1044.